Simcere is one of the earliest Chinese pharmaceutical companies to invest in new drug R&D. In 2000, the Simcere New Drug Research Center was established, which had further evolved into a modernized pharmaceutical research institute since 2003 (now Nanjing R&D Institute). Our R&D sector had independently developed a series of innovative drugs and first-to-market generic drugs such as Iremod® and BICUN®. Over the years, we have insisted on putting a large and increasing percentage of our revenue (8% to 10%) into R&D. In 2018, Simcere Shanghai (Boston) Innovation Center was founded, aiming at leveraging global innovation resources and seeking more effective treatments for our patients.
R&D Directions
Cancer:pharmacodynamics and translational study for indication selection based on CTC technology and the PDX model
Autoimmune disease:correlation study between body fluid biomarkers and specific drug candidates
CNS diseases:Correlation study between animal models and stroke prognosis
R&D platforms
Generation sequencing platforms
Companion diagnostics platforms
Bioinformatics platforms
Pipelines for Innovative Drugs
Therapeutic area
Project name
Immunology SIM-126
Oncology SIM-159-1
Oncology SIM-63
Oncology SIM-1809-19
Oncology SIM-1812-02
Oncology SIM-1904-04
Oncology SIM-1902-03
Oncology SIM-1902-04
Oncology SIM-159-2
Oncology SIM-159-3
Oncology SIM-159-4
Oncology SIM-1803-1
Oncology SIM-1804
Pipelines for Generic Drugs
Therapeutic area
Project name
BE/Clinical Study
Oncology SIM-116-3
Infection SIM-146
Infection SIM-147
Muscle-skeletal SIM-145
CNS SIM-117-13
Oncology SIM-58
Nephrology SIM-1915-01
Infection SIM-148
Immunology SIM-117-11
Infection SIM-143
Muscle-skeletal SIM-139
Respiratory SIM-132
Oncology SIM-138
Oncology SIM-150
Oncology SIM-1809-1
Oncology SIM-1808-2
Oncology SIM-1809-10
Oncology SIM-1902-01
Infection SIM-117-17
Infection SIM-141
Infection SIM-1809-2
Infection SIM-1903-01
CVS SIM-1809-18
Nephrology SIM-1808-1
Immunology SIM-1809-8
Anti-inflammation SIM-166
Immunology SIM-1809-9
CNS SIM-1904-08
Oncology SIM-1904-09
Oncology SIM-1904-11
Oncology SIM-1904-12
Respiratory SIM-1904-07
Anti-coagulation SIM-1904-15
Anti-coagulation SIM-1904-10
Anti-TB SIM-1904-13